A vaccine advisory committee for the Food and Drug Administration will review whether to recommend two vaccines for respiratory syncytial virus for approval next week as pharmaceutical giant Pfizer and rival drug manufacturer GSK vie to have the first RSV vaccine to hit the U.S. market.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.